Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
July 29, 2024 7:18 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "BMY's noteworthy outperformance on Friday July 26 (+~11% vs. flat XLV), while it occurred amidst favorable shifts in the broader market macro backdrop, was earned, in our... More
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, provides guidance
July 26, 2024 7:02 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.07, $0.43 better than the analyst estimate of $1.64. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.52 billion.
GUIDANCE:
Bristol-Myers Squibb sees Q3 2024 EPS of $0.60-$0.90, versus the consensus of... More
Bristol Myers second-quarter results beat expectations, helped by new drugs
July 26, 2024 7:00 AM EDTBy Michael Erman
(Reuters) - Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.
Eliquis is expected to have revenue curtailed when the U.S. Medicare health plan for people over age 65 institutes negotiated drug prices starting in 2026. President Joe Bidens signature Inflation Reduction Act (IRA), signed into law last year, allows Medicare to negotiate prices for some of its most costly drugs.
Bristol Myers Chief Executive Chris Boerner said the company has... More
PCE release, Apple's Chinese sales, European earnings - what's moving markets
July 26, 2024 4:12 AM EDTInvesting.com -- Wall Street looks set to end a difficult week on a bright note, although the release of the Federal Reserve's favorite inflation gauge later in the session could influence sentiment. Apple is losing market share in the important Chinese market, while European corporate earnings continue to flow.Â
1. Key PCE inflation data dueÂ
The spotlight Friday will be on the Federal Reserves preferred gauge of inflation, which could test market expectations that the U.S. central bank is all but certain to cut interest rates in... More
Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results
July 25, 2024 10:47 AM EDTBristol-Myers Squibb (NYSE: BMY) July 26 weekly call option implied volatility is at 101, August is at 38; compared to its 52-week range of 16 to 34 into the expected release of quarter results before the bell on July 26.
... MoreBristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle into quarter results
July 25, 2024 5:14 AM EDTBristol-Myers Squibb (NYSE: BMY) July 26 weekly 44.5 straddle priced for a move of 4.5% into the expected release of quarter results before the bell on July 26.
... MoreBristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle priced into quarter results
July 25, 2024 5:08 AM EDTBristol-Myers Squibb (NYSE: BMY) July 26 weekly 44.5 straddle priced for a move of 4.5% into the expected release of quarter results before the bell on July 26.
... More